Ligand shares relisted on Nasdaq

By Lisa Kerner

Charlotte, N.C., June 12 - Ligand Pharmaceuticals Inc. said that Nasdaq has approved the company's application for relisting its common stock on the Nasdaq National Market.

Trading of Ligand's common shares on the Nasdaq National Market is expected to begin June 14 under the symbol "LGND."

San Diego-based Ligand discovers, develops and markets drugs for the treatment of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.